In the United States<unk>  is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. In the European Union<unk>  is indicated in adults aged 18 years and older with type 2 diabetes mellitus: * to improve glycemic control when metformin and/or sulphonylurea (SU) and empagliflozin or<unk>  do not provide adequate glycemic control; * when already being treated with the free combination of empagliflozin and<unk> .
Empagliflozin/linagliptin
Dapagliflozin/saxagliptin
Canagliflozin/metformin
Empagliflozin/metformin
Dapagliflozin/saxagliptin/metformin
Pioglitazone/metformin
Dapagliflozin/metformin
Pioglitazone/glimepiride